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Summary The present study represents a continuation of previous works in which we observed that lung carcinomas co-expressing MDM2
protein and p53 mutants (mt p53) exhibited more aggressive behaviour. In the above studies, we suggested a 'gain offunction' mechanism of
mt p53 proteins based on the fact that the MDM2 gene possesses a p53-responsive element (MDM2-p53RE). In this study, to prove our
hypothesis, we selected 12 cases from a series of 51 bronchogenic carcinomas. In these 12 cases, we examined the ability of the expressed
mt p53 to bind the MDM2-p53RE and correlated the findings with MDM2 expression. Furthermore, we constructed four of these p53 mutants
and studied their transactivation properties by co-transfecting them with a reporter plasmid carrying MDM2-p53RE in the p53 null non-small-
cell lung carcinoma cell line (NSCLC) H1299. We observed mutant p53 protein DNA-binding activity, which depended on the nature and the
position of the amino acid substitution. The fact that the cases with DNA-binding activity were accompanied with MDM2 protein isoforms'
overexpression is indicative of a 'gain of function' phenotype. This hypothesis was enforced by the findings of the transfection experiments,
which revealed that certain p53 mutants enhanced the expression of the luciferase reporter gene either directly or indirectly via a dominant
positive effect on the wild-type p53. In conclusion, this work is one first attempt to examine ifthe deregulation of the p53/MDM2 autoregulatory
feedback loop is due to novel properties of certain p53 mutants in the specific environment of a subset of bronchogenic carcinomas.
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The p53 oncosuppressor gene is mapped to chromosomal region
17pl3 and encodes a 393 amino acid (aa), 53-kDa nuclear phos-
phoprotein. The protein is divided into three main structural and
functional domains. The first 42 amino acids at the N-terminus
constitute the transactivation domain, the residues between amino
acids 120 and 290 make up the sequence-specific DNA binding
domain, whereas residues 310-393 at the C-terminus contain the
nuclear localization signals, the tetramerization domain and the
extreme carboxy-terminus that allosterically regulatesp53 specific
DNA binding. p53 protein is involved in vital aspects of the cell
life, such as control of cell cycle checkpoints G, and G2, main-
taining genomic integrity, DNA repair, replication, transcription,
programmed cell death (apoptosis) and differentiation. Functional
loss ofp53, mostly via mutations, is considered the most common
genetic lesion in human cancer (Greenblatt et al, 1994). Therefore,
an understanding of the functions of p53 may help elucidate key
steps in carcinogenesis. The cellular effects of p53 are mediated
eitherby protein-protein interaction orby binding to DNA regula-
tory elements. In the first case, p53 interacts with factors of the
replication, transcription and repair machinery (reviewed by:
Zambetti and Levine, 1993; Gottlieb and Oren, 1996; Ko and
Prives, 1996; Oren and Prives, 1996; Levine, 1997). In the second,
it binds to specific DNA sites made up of two copies of the
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following sequence: 5' (Pu)3C(A/T)(A/T)G(Py)3 3' (Funk et al,
1992). The list of genes that possess these DNA sites is rapidly
increasing and includes: waf-J/cip-J (El-Deiry et al, 1993),
gadd45 (Kastan et al, 1992 and references therein), MDM2
(Zauberman et al, 1995a), bax (Miyashita and Reed, 1995), cyclin
G (Zauberman et al, 1995b), insulin-like growth factor binding
protein 3 (IGF-BP3) (Buckbinder et al, 1995), epidermal growth
factor receptor (EGF-r) (Deb et al, 1994), transforming growth
factor-a (TGF-a) (Shin et al, 1995), proliferating cell nuclear
antigen (PCNA) (Morris et al, 1996), thrombospondin-J (Dameron
et al, 1994),fas/APO-1 (Owen-Schaub et al, 1995), Rb (Osifchin
et al, 1994), cyclin D (Chen et al, 1995), ras (Spandidos et al,
1995; Zhang et al, 1995) andp53 itself(Deffie et al, 1993).
The MDM2 gene is located on chromosomal region 12ql3-14
and has the characteristic of generating various MDM2 proteins
(Olson et al, 1993). The full-length MDM2 gene product p90
forms an autoregulatory feedback loop with p53, which seems to
be critical for normal cell proliferation (Wu et al, 1993; Oca Luna
et al, 1995). The functions of the other MDM2 proteins are
currently unknown. The expression of different MDM2 protein
isoform pattems in leukaemias and lymphomas (Bueso-Ramos et
al, 1995a), sarcomas (Bueso-Ramos et al, 1995b), breast (Bueso-
Ramos et al, 1996) and lung carcinomas (Gorgoulis et al, 1996b)
but not in normal tissue, suggests that certain MDM2 proteins may
play a role in the oncogenic process. Interestingly, in leukaemias,
lymphomas, sarcomas and ovarian carcinomas (Foulkes et al,
1995), MDM2 overexpression does not accompanyp53 mutations
or overexpression, suggesting a novel p53-independent pathway
ofaction.
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Table 1 Binding ability of mutant p53 proteins to p53-responsive element of the MDM2gene
Group Sp. Dx Grade IHC p53 mutations LOH D-PCR Bin.ab. Mdm2 mRNA Mdm2protein
p53 Exons CodJBas.Sub. Aa Sub. level products
A 1 Sq MD +++ 5 157, GTC-*TTC V-*F + - + T A, B, C
2 Sq MD +++ 7 234, TAC-*TGC Y'-C + - + 1 A, C
3 Ad PD +++ 5 158, CGC->GGC R->G + - - 1 B, C
4 Ad MD +++ 7 258, GAA-*GGA E-*G + - - 1 B, C
5 SCLC - +++ 6 209, AGA-*ACA R-*T + - + T B
B 6 Ad PD +++ 5 138, GCC-*GAC A-*D + - - - -
7 Sq MD +++ 5 138, GCC-*CCC A-*S + - - - -
8 Sq PD +++ 5 173, GTG-*GAG V-1E + - - - -
C 9 Sq MD - 5 195, ATC->AATC FS + - - - -
10 Sq PD +++ 8 273, CGT-*CAT R-*H - - + 1 C
11 Ad MD +++ 8 275, TGT-*TAT C-*Y - - + T A, C
12 Ad MD +++ - - - - - + T A, B, C
Abbreviations, Sp., specimen; Dx, diagnosis; Sq, squamous cell carcinoma; Ad, adenocarcinoma; SCLC, small-cell carcinoma; MD, moderately differentiated;
PD, poorly differentiated; IHC, immunohistochemistry; Cod, codon; Bas.Sub, base substitution; Aa Sub., amino acid substitution; FS, frameshift; LOH, loss of
heterozygosity; Bin. ab., binding ability; A, p57; B, p76/74; C, p90.
Recently, we reported that MDM2 protein isoforms are over-
expressed and coexist with the mutant p53 protein (mt p53) in a
subset of bronchogenic carcinomas. This association was
accompanied with a more aggressive behaviour (Gorgoulis et al,
1996a,b). We suggested that this may be indicative of mt
p53-MDM2 complex activity (Momand et al, 1992) or may reflect
a 'gain of function' phenotype. The last hypothesis is based on
recent studies that show that mtp53 does not only act by dominant
negative inhibition of wild-type p53 (wt p53) (Hinds et al, 1989;
Milner et al, 1991) but also exerts oncogenic properties of its own
(Michalovitz et al, 1991; Chin et al, 1992; Dittmer et al, 1993;
Hsiao et al, 1994; Muller et al, 1996). One putative mechanism by
which mtp53 could acquire tumorigenic properties is to constantly
stimulate growth-promoting genes that contain the p53-specific
DNA binding site. This could be achieved if the mt p53 main-
tained its ability to bind and transactivate the above-mentioned
DNA elements.
Inthepresent study, weexaminedthelasthypothesis bytesting the
ability of mt p53 forms, detected in selected cases of bronchogenic
carcinomas, to bind the p53-responsive element (p53RE) of the
growth-promoting gene MDM2 and correlating the findings with its
expression. Furthermore, we constructed four of these p53 mutants
and studied their transactivation properties by co-transfecting them
with a reporter plasmid carrying the MDM2-p53RE in the p53 null
non-small-cell lung carcinoma cell line (NSCLC) H1299.
MATERIALS AND METHODS
Tissue samples
Fifty-one bronchogenic carcinomas were taken shortly after
surgery. Two samples of each tumour were obtained. One was
snap frozen in liquid nitrogen and stored at -70°C; the other was
formalin fixed and paraffin embedded (FFPE). In addition, adja-
cent normal tissue was included from each specimen examined.
The patients had not undergone any chemo- or radiotherapy before
surgical resection, thus avoiding up- and down-regulation of p53
and MDM2 proteins (Price and Park, 1994), respectively, due to
DNA damage. Tumours were classified according to the World
Health Organization (1984) criteria.
Experimental planning
To prove our hypothesis, we examined p53 and MDM2 proteins,
using a series ofmethods, in all the above 51 cases. We selected 12
carcinomas, placed in three groups, that fulfilled the following
specific criteria:
Group A (five carcinomas) (cases 1-5, Table 1)
(a) Cancerous tissue made up more than 90% of the tissue block.
Contamination from stromal cells was avoided by delineating
stereoscopically and microscopically the boundaries ofthe malig-
nant area and removing excess normal tissue. (b) They expressed
immunohistochemically p53 and MDM2 in almost all the
cancerous cells. (c) Western blot analysis confirmed p53 and
MDM2 overexpression and revealed the isoforms that the MDM2
gene expressed. (d) The single-strand conformation polymorphism
(SSCP) technique, followed by solid-phase sequencing, revealed
p53 gene alterations. (e) Southern blot analysis with the poly-
morphic marker pYNZ22 showed loss ofheterozygosity (LOH) of
chromosome region 17pl3, which encodes the p53 gene. These
criteria were set in order to study a cancerous population that
uniformly expressed the MDM2 gene products and mtp53 protein,
as the remaining normal p53 allele was lost.
Group B (three carcinomas) (cases 6-8, Table 1)
The criteria were the same as in group A with the exception that
MDM2 protein was not expressed.
Group C (fourcarcinomas) (cases 9-12, Table 1)
We decided to form this group, although its members did not
srtictly obey the conditions set above for reasons analysed in the
discussion.
Antibodies
For immunohistochemical, immunoblotting, immunoprecipitation
and EMSA analysis the following monoclonal antibodies (mAbs)
were used: D07 (class: IgG2b, epitope: residues 1-45 of p53)
(Dako, Denmark), DOI (class: IgG2a, epitope: residues 21-25 of
p53) (kindly provided by Dr DP Lane, Dundee, UK), PAb421
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(class: IgG2a, epitope: residues 371-380 of p53), (Oncogene
Science, NY, USA), IB1O (class: IgM, epitope: -COOH terminal
position ofMDM2) (Novocastra Laboratories, UK) and IF2 (class:
IgG2b, epitope: -NH2 terminal position of MDM2) (Oncogene
Science, NY, USA).
MDM2 and p53 immunohistochemistry (IHC)
Immunohistochemical analysis was performed on tissue
sections using the streptavidin-biotin-peroxidase method (Dako,
Denmark). p53 and MDM2 protein were unmasked with the
heat-mediated antigen retrieval (HMAR) method, as previously
described (Gorgoulis et al, 1996a, b). Visualization was carried out
with diaminobenzidine as chromogen. Laryngeal carcinomas
expressing p53 and a leukaemic cell line, K562, overexpressing
MDM2 (Bueso-Ramos et al, 1993) were used as positive controls.
Mouse IgGI mAb of unrelated specificity and the IgG fraction of
normal rabbit serum were used as negative controls. The p53,
MDM2-positive cases were classified using the following semi-
quantitative method: 0, negative; (+), <20% positive cells (mild);
(++), 20-75% positive cells (moderate); (+++), >75% positive
cells (intense).
Simultaneous extraction of nuclear proteins and DNA
The samples were homogenized in a hypotonic buffer [25 mM
Tris-HCl pH 7.5, 5 mM potassium chloride, 0.5 mm magnesium
chloride, 0.5 mm dithiothreitol (DTT), 0.5 mm polymethyl-
sulphonyl fluoride (PMSF)] at 5-10 mg ml-l. The nuclei were
collected in a pellet at 2500 r.p.m. for 10 min at 4°C, washed three
times with an isotonic buffer (25 mm Tris-HCl pH 7.5, 5 mm
potassium chloride, 0.5 mm magnesium chloride, 0.2 mm sucrose,
0.5 mM DTT, 1 mm PMSF) and resuspended in nuclear extraction
buffer (25 mm Tris-HCl pH 7.5, 1 mm EDTA, 0.1% NP-40, 0.5mM
DTT, 0.5 mm PMSF). Nuclear extracts were clarified after
centrifugation at 25 000 r.p.m. for 60 min at 40C. Supematant
containing the extracts was stored at -70°C. DNA was extracted
from the final pellet, which contained a mixture of nucleic
acids and nuclear debris, according to standard protocols
(Sambrook et al, 1989).
Nested-PCR/SSCP and solid phase sequencing of p53
gene
Nested PCR and SSCPanalysis
The methods were performed on matched normal and tumour
DNA, as described previously (Gorgoulis et al, 1995a). Briefly, we
first determined the optimal conditions for amplification of the
2.9 kbp53 gene fragment, which contains exons 4-9, and then we
amplified individual exons, with nested PCR, using biotinylated
sense primers. Next, we analysed, using the SSCP technique,
exons 4-9, as themajority ofprevious studies have shown thatp53
mutations in lung carcinomas are found in this region (Greenblatt
et al, 1994). The exons that showed mobility shifts were further
analysed with solid-phase sequencing.
Immobilization ofthe PCRproduct
The biotinylated PCR product was immobilized on magnetic
beads covalently coupled with streptavidin (Dynabeads M-280-
streptavidin, Dynal, Oslo, Norway) using aneodynium-iron-boron
permanent magnet (Dynal, Oslo, Norway). Briefly, 40g1 of PCR
product was added to 40gl of dynabeads M-280 streptavidin and
was incubated for 30 min at room temperature (RT). The beads
were previously washed with 2X binding and washing buffer (2X
B&W) (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 2 M sodium chlo-
ride). Then, the mixture containing the complex was placed in the
magnet. The supernatant was removed and 8 p1 0.1 N sodium-
hydroxide was added. The sodium hydroxide supematant
containing the eluted single strand was placed in a new tube and
neutralized with 0.2 N hydrochloric acid and 1 M Tris-HCl pH 7.5.
The remaining immobilized single strand was washed once with
0.1 N sodium hydroxide once with lxB&W buffer and once with
TE (10 mM Tris-HCl pH 7.4, 0.1 mM EDTA pH 8) and diluted in
7 p1 ofdouble-distilled water.
Sequencing
Direct sequencing of the eluted and immobilized strand was
carried out with standard dideoxy termination reactions using the
Sequenase version 2.0, DNA Sequencing kit (US Biochem,
Cleveland, USA). In brief, 2 ul (2 pmol) ofsequencing primer was
added to each single-strand tube together with 2 pl of annealing
buffer. The annealing mixture was heated for 2 min at 65'C and
allowed to cool to RT for 30 min. Then 2 pl of diluted labelling
mixture (dGTP, dCTP, dTTP), 0.5 p1 of [a-35S]dATP and 2 pl
(2.5 U 1-1) ofT7 DNA polymerase were placed in each annealing
mixture and prewarmed for 2 min at RT. Consequently, 3.5 p1 of
the reaction was added to four tubes containing 2.5 p1 of the
termination mixtures and were incubated for a further 5 min. The
reactions were stopped with a solution containing formimide.
Termination reactions were heated for 2 min at 90°C and 2-3 p1
was run on a 8% polyacrylamide denaturating gel. The gels were
dried and exposed to radiograph film (RX Fuji) at RT.
The sequencing primers used were the following. For exon 5:
biotinylated strand, 5'-TTC AAC TCT GTC TCC TTC CT-3' and
non-biotinylated strand, 5'-CAG CCC TGT CGT CTC TCC AG-
3'; for exon 6: biotinylated strand, 5'-GCC TCT GAT TCC TCA
CTG AT-3' and non-biotinylated strand, 5'-TTA ACC CCT CCT
CCC AGA GA-3'; for exon 7: biotinylated strand, 5'-TGT GCA
GGG TGG CAA GTG GC-3' (non-biotinylated strand-sequencing
was not performed), and for exon 8: biotinylated strand: 5'-TTC
CTT ACT GCC TCT TGC TT-3' and non-biotinylated strand: 5'-
TGA GGC ATA ACT GCA CCC TTG GT-3'.
Southern blot analysis for LOH of the chromosomal
region 17p13.3
An aliguot (10 jig) of DNA was digested with PstI (Boehringer
Mannheim Biochemica, Mannheim, Germany). The resulting
fragments were subjected to electrophoresis in 0.8% agarose gels,
transferred to nylon membranes (Hybond-N, Amersham) and
baked for 3 h at 800C. The membranes were hybridized to random
primer [32P]dCTP-labelled pYNZ22 probe, which locates chromo-
somal region 17pl3.3. This probe detects restriction fragments
length polymorphisms on PstI and BamHI digested DNA. After
hybridization, the membranes were washed under stringent condi-
tions (0.2 x SSC at 65°C for 20 min) and autoradiographed.
Differential PCR (D-PCR) for MDM2gene amplification
D-PCR was carried out as described previously (Gorgoulis et al,
1995b). As target and reference sequences we used a 150-bp and
a 230-bp fragment of the MDM2 (Fontana et al, 1994), and
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interferon-,y (IFN-y) (Gorgoulis et al, 1995b) respectively. The
primer sequences for the 230-bp MDM2 gene fragment were
the following: 5'-TGAGTGAGAACAGGTGTCACC-3' (sense)
and 5'-TTCTAGATGAGGTAGATG-3' (antisense). A leiomyo-
sarcoma carrying an eightfold MDM2 gene amplification was used
as positive control.
RNA extraction - MDM2 Northern blotting
RNA was extracted from the specimens using the RNazol B
reagent (BioGenesis) and Northern blot hybridization was
performed with a 585-bp MDM2 [32P]dCTP-labelled probe span-
ning nucleotidies 650-1214 of the published cDNA sequence as
described previously (Gorgoulis et al, 1996a).
MDM2 and p53 Western blot analysis - MDM2
immunoprecipitation
An aliquot (20gg) ofnuclear proteins was electrophoresed on 10%
polyacrylamide-SDS gel andtransferred to nitrocellulose membrane
(Sambrook et al, 1989). Blots were blocked for 2 h in 5% non-fat
dry milk/PBST (PBST: PBS, 0.1% Tween-20) at RT. Subsequently,
the membranes were incubated overnight with IBlO and IF2 anti-
bodies (diluted 1:500) and DOI (diluted 1:1000) at4°C. Fordetec-
tion, the biotinylated rabbit anti-mouse immunoglobulin (1:100)
(Dako, Denmark) and streptavidine-biotin-peroxidase complex
(Dako, Denmark) were applied. The MDM2 and p53 levels
were analysed using an enhanced chemiluminescence system
(Amersham, Arlington Heights, IL, USA). Protein from a
leiomyosarcoma, overexpressing MDM2, and normal lung tissue,
with undetectable levels of MDM2 protein were used as positive
and negative control respectively. Protein from the HT29 colon
cancer cell line, which overexpresses p53, was used as a positive
control (American Type Culture Collection). Band sizes were
determined by comparison to migration of broad range protein
ladder (Biolabs, MA, USA). Protein levels ofMDM2 were scored
by eye on a relative basis as follows: 0, negative; (+), low levels;
(++), elevated levels.
The specificity ofthe bands immunoblotting showed, was veri-
fied by immunoprecipitating the nuclear extracts from the selected
cases. Immunoprecipitation was performed using protein A-
Sepharose (Sigma), according to standard protocols (Sambrook et
al, 1989). Immunoprecipitates were then separated on a 10% poly-
acrylamide gel and immunoblotted.
Electrophoretic mobility shift assay (EMSA)
Thep53REofthe MDM2gene
The p53RE of the MDM2 contains two p53 binding sites (under-
lined italic regions), separated by 18 nucleotides (Zauberman et al,
1995a). The sequence of this region is: 5'-TTGAGCT-
GGTCAAGTTCAGACACGTTC-CGAAACTGCAGTAAAAG-
GAGTTAAGTCCTGACTTTGTCT-CCAGCTC-3'. The above
oligonucleotides (sense, anti-sense) were synthesized on a
Cyclone Plus synthesizer (Milligan Bioresearch, MA, USA). End-
labelling was performed using T4 polynucleotide kinase
(Boehringer, Mannheim, Germany) and [a-32P]ATP according to
standard protocols (Sambrook et al, 1989). The end-labelled
oligonucleotides were mixed in 0.1 M sodium chloride, heated at
950C for 5 min and then gradually cooled to RT to allow
annealing.
Controls
In vitro translated p53 protein was used as a positive control in
the DNA binding experiments. Briefly, the procedure was the
following: the expression vector pGEMhp53wtB was linearized
by digestion with BamHI. Capped transcripts were prepared using
T7 RNA polymerase (Promega) and then translated in reticulocyte
lysates as recommended by the supplier (Promega). Successful
translation was verified by Western blotting using antibody DOI.
The SP-1 oligonucleotide was used as a p53-unrelated oligo-
nucleotide competitor.
DNA binding assay
Three microlitres ofnuclear extracts (10 jg) was preincubated for
10 min with 100 ng of purified monoclonal antibody PAb421 to
activate specific DNA binding of p53 protein. It has been shown
that p53 binds non-specifically to DNA through the carboxy-
terminal domain, locking p53 in a conformation that cannot bind
its specific element. By adding PAb421, non-specific binding is
inhibited and p53 adopts the specific DNA conformation
(Halazonetis et al, 1993; Bayle et al, 1995). Furthermore, nuclear
extracts from p53 null cells (Saos2) were added to the reaction, in
order to get in vitro translated p53 to bind the p53RE (Funk et al,
1992). Subsequently, 1 ng of labelled p53RE in the presence of
500 ng ofpoly(dI)-poly(dC) as non-specific DNA competitor was
added. All incubations took place on ice with the following
binding conditions: 50 mm potassium chloride, 25 mm Hepes,
pH7.6,5 mmDTT, 10 jg ofleupeptin perml, 0.05% Triton X-100
and 20% glycerol. Competition experiments were performed by
preincubating PAb421-activated extracts with 50-fold molar
excess of unlabelled oligonucleotides (pS3RE or SP-1) or 100 ng
of anti-p53 antibody DO1. Protein-DNA binding reactions were
analysed on a 4% polyacrylamide gel. Gels were dried and
exposed on radiograph film (RX Fuji) at-70°C.
Transfection assays
Cell line andplasmids
H1299 cells (a human non-small-cell lung carcinoma cell line that
contains a homogeneous deletion of the p53 gene) were obtained
from the American Type Culture Collection (Rockville, MD,
USA) and maintained in RPMI-1640 medium supplemented with
10% fetal calf serum in a 37°C incubator containing 5% carbon
dioxide. Reporter plasmid pGL2hmdm-HX-luc was constructed,
as described previously (Zauberman et al, 1995a), by excising the
HindIII-XhoI fragment from the amplified hMDM2 DNA, and
subcloning it into pGL2-Basic (Promega). The representative p53
mutants, V157F, R209T (group A), V173E (group B) and R273H
(group C), were generated by site-directed mutagenesis of the
parental wtp53 vector pCB6p53wt. The pCB6p53wt plasmid
contains the published p53 cDNA sequence (Matlashewski et al,
1984; Zakut-Houri et al, 1985).
Site-directed mutagenesis
The site-directed mutagenesis procedure we followed was based on
the method of Deng and Nickoloff (1992). This method works by
simultaneously annealing two oligonucleotide primers to one strand
of a denaturated double-strand plasmid. One primer introduces the
desired mutation (mutagenic primer), whereas the othereliminates a
unique restriction site of the plasmid for the purpose of selection
(selection primer). Aftersynthesis ofahybridplasmid and aprimary
selection by digesting with the appropriate restriction enzyme, the
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Figure 1 Analysis of the interaction between mutant p53 protein, R209T, produced in sample 5 and p53 responsive element (p53RE) of the MDM2 gene.
(A).Position of p53 mutation in case 5, obtained by direct sequencing of the nested-PCR product of exon 6 (arrow). The mutation changes codon 209 from
TCT (R) to TGT (T) (antisense strand). The left-hand sequence represents wild-type DNA. N, normal; T, tumour. (B) Electrophoretic mobility shift assay showing
sequence-specific binding of the mutant p53, R209T, to the p53RE of the MDM2 gene. Lane 1, mutant p53 R209T binds with the specific DNA, in the presence
of PAb421, and forms a retarded band (middle arrow). The specificity of the band was demonstrated with the following reactions. Lane 2, 50-fold molar excess
of unlabelled MDM2-p53RE probe, in the presence of PAb421, markedly diminished the retard band. Lane 3 (control), in vitro translated wild-type p53 was
incubated with labelled p53-RE, in the presence of PAb421, and produced a retard band at the same height as R209T.*: In the last reaction we added nuclear
extracts from the p53 null cell line Saos2 to achieve p53 specific binding (Funk et al, 1992). Lane 4, the addition of anti-p53 antibody DO-1, in the presence of
PAb421, super-shifted the retard band indicating the presence of p53 in the protein-p53 complex (Niewolik et al, 1995) (upper arrow). (C) Western blotting with
antibody 1Bl0 showing the MDM2 protein isoform p76/74 expressed in sample 5 (lane 5). Lanes 1-4 represent MDM2 proteins produced from cases included
in our previous work (Gorgoulis et al, 1996b)
hybrid plasmid is transformed into amutS E. coli strain defective in a
mismatch repair. This step is followed by an amplification procedure
that results in a large pool of mutated and parental plasmids. The
isolated DNA is then subjected to a series of selective restriction
enzyme digestions thatdestroy theparental plasmid. A final transfor-
mationusing thethoroughly digestedDNA willresultinthe recovery
ofthe desired mutant plasmid. In the present study, we used a selec-
tive primer which eliminates the unique NdeI restriction site and
introduces an NcoI restriction site in the parental plasmid
pCB6p53wt, and mutagenic primers:
for V157F: 5'-GGCACCCGCTTCCGCGCCATGGC-3'
for R209T: 5'-TTGGATGACACAAACACTlTTCGAC-3'
for V173E: 5'-GACGGAGGTTGTGAGGCGCTGCC-3'
and
for R273H: 5'-GCTTTGAGGTGCA TGTTTGTGCCTG-3'
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Table 2 Transcriptional transactivation by mutant p53 proteins with pGL2hmdm-HX-luc reporter
Transfected DNA Change Per cent of pGL2hmdm-HX-lu
activity
from: to:
pCB6 (control) 15
pCB6p53wt (wtp53) - 100
pCB6p53mt V157F (mtp53-V157F) GTC TTC 72
pCB6p53mtR209T (mtp53-R209T) AGA ACA 21
pCB6p53mtVl73E (mtp53-V173F) GTG GAG 14
pCB6p53mtR273H (mtp53-R273H) CGT CAT 12
wtp53/mtp53-R273H: 1/1 40
wtp53/mtp53-R273H: 1/4 61
The E. coli bacterial strains we used for the first and final transfor-
mation were BMH71-18 mutS and XLl-Blue respectively.
Successful mutagenic procedure was verified by sequencing.
Transient transfections andluciferase assay
One microgram of the reporter plasmid pGL2hmdm-HX-luc was
mixed with 1 ug of the expression vectors encoding wt p53, mt
p53 V157F and R209T (group A), mt p53 V173L (group B), mt
p53 R273H (group C) and control vector, pCB6, respectively, in
RPMI-1640 medium. An aliquot (10 jg) of diluted in RPMI
(1:100) Transfectam reagent (Promega) was immediately added
to the plasmid mixture. The Transfectam reagent is a synthetic,
cationic lipopolyamine with high affinity for DNA, coating it with
a cationic lipid layer that facilitates binding to the cell membrane.
The Transfectam/plasmid mixture was then added directly to 5 x
105 exponentially growing H1299 cells in RPMI-1640 medium
(without serum). The cells were incubated at 37°C with 5% carbon
dioxide for48 h. The transfected cells were collected, washed with
phosphate-buffered saline, and lysed in the lysis buffer provided
with the luciferase kit (Promega). Transcriptional activity was
measured using a luminometer (Pharmacia LKB Nuclear,
Gaithersburg, MD, USA). Successful transfection was verified by
Western blotting using antibody DOI.
RESULTS
Immunohistochemical and molecular profile of p53 and
MDM2 proteins in the selected bronchogenic
carcinomas (Table 1)
The data concerning the characteristics ofp53 and MDM2 proteins
in the selected cases ofgroups A (cases 1-5), B (cases 6-8) and C
(cases 9-12) are presented in detail in Table 1. All the mutations
were single-base substitutions and missense (six transversions and
four transitions) (Figure lA) with the exception of a frame-shift
mutation detected in case 9. In cases 1-4, they were located in the 3
sandwich of the p53 protein (S4, S8, S4 and S9, respectively, Cho
et al, 1994) that forms a scaffold to support the DNA-binding
domain. This region ofp53 is less conserved than the DNA-binding
domain and possesses less than 1% ofallp53 mutations. Mutations
detected in this area are known as conformational. In specimen 5,
the mutation was also conformational with the difference that it
occurred in a 5-turn connecting S6 and S7 (Cho et al, 1994). The
mutations in group B and in specimens 10 and 11 ofgroup C were
located in the DNA-binding domain and are classified as contact
mutants (Cho et al, 1994). This region accounts for the majority of
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Figure 2 Effects of the p53 mutants on the transcriptional activity of the
luciferase reporter gene downstream of the MDM2-p53RE of the
pGL2hmdm-HX-luc plasmid. The total amount of DNA transfected in each
experiment was 2 gg (1 9g of wt and/or mt p53 and 1 gg of the reporter
plasmid). Activity was expressed as a percentage of that induced by 1 ig of
wt p53. Results shown are an average of three independent transfection
experiments
all p53 mutations. Notably, in case 12, although IHC and
immunoblotting showed p53 overexpression, direct sequencing did
not indicate any alteration in the p53 gene, therefore it expressed
the wt p53 protein. Immunoblotting analysis, in the specimens that
expressed MDM2, revealed various patterns of three MDM2
protein isoforms ofapproximately 90 kD (p90), 76/74 kD (p76/4),
and 57 kD (p57) (Figure 1C). D-PCR analysis showed that overex-
pression ofthe MDM2 proteins was due to increased transcription
and not to MDM2 gene amplification.
DNA binding properties of mutant p53 proteins
(Table 1)
Group A
DNA-binding experiments revealed in cases 1, 2 and 5 a common
retard band (Figure IB, lane 1). This band was supershifted when
anti-p53 antibody DO1 was included in the reaction mixture
(Figure iB, lane 4) and abolished in the presence of excess unla-
belled p53RE (Figure iB, lane 2). Competition with molar excess
of SP-1 did not abolish the band. These findings indicated the
presence of p53 in the protein-DNA complex (Niewolik et al,
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Figure 3 Schematic representation of the mechanisms we suggest that deregulate the p53/MDM2 autoregulatory feedback loop in a subset of bronchogenic
carcinomas. Comparison with the p53/MDM2 autoregulatory feedback loop that exists in normal cells. (A) In a normal cell not under stress wild-type p53
(wt p53) protein is expressed at very low levels and plays little role in the normal cell cycle (Vogelstein et al, 1992). The MDM2gene isvery weakly stimulated
by wt p53 and the low levels of the MDM2 protein p90 are produced mainly due to the basal activity of the P1 promoter (Zauberman et al, 1995a). (B) In a
normal cell under stress (DNA damage, hypoxia, metabolic changes and immunological response), the MDM2gene is expressed only when wt p53 has
activated the targets that mediate its 'protective' action (e.g. gadd45, waf-1/cip-1). When the cell contains relatively large amounts of wt p53, it binds transiently
the p53 RE of MDM2, triggerng the production of MDM2 protein p90 that eventually terminates p53 cycle arrest mediated signal (reviewed by Gottlieb and
Oren, 1996; Ko and Prives, 1996; Oren and Prves, 1996; Levine, 1997). Furthermore, p90 promotes the cell cycle by inactivating the oncosuppressor protein
Rb (Xiao et al, 1995) and enhancing the activity of the S-phase inducing transcription factor E2F1 (Martin et al, 1995). (C) In the environment of a lung
carcinoma cell the following oncogenic mechanisms may possibly develop: 1. Constantly elevated levels of mutant p53 proteins permanently stimulate the
MDM2 gene (directly or indirectly, see Discussion) producing high levels of MDM2 mRNA. Excess MDM2 mRNA is probably responsible, via a complex dose-
dependent mechanism (Zauberman et al, 1995a; Barak et al, 1994), for the production of various MDM2 proteins, several of which do not form an
autoregulatory loop with p53 (Gorgoulis et al, 1996b). The overexpressed p90 isoform positively augments cell proliferation by interacting with E2F1. The other
MDM2 proteins, probably, add novel oncogenic properties to the cell (Shigalas et al, 1996). 2. Inactive mt p53 proteins exert a dominant positive effect on the
transcription activity on the wt p53 protein. 3. Alterations at the P1 promoter may activate a p53-independent mechanism of MDM2 overexpression. 4. Mutant
p53 has the ability to complex with the MDM2 p90 isoform enhancing probably the tumorigenic potential (Momand et al, 1992)
1995) and revealed that p53 mutants V157F, Y234C and R209T
(Fig. lA) maintained the wild-type p53 property to bind the
MDM2-p53RE. Interestingly, the substituted amino acids in the
first two specimens possessed similarresidual (-R) groups. In case
1, the hydrophobic non-polar Val was replaced by Phe and in case
2 the hydrophilic uncharged Tyr was replaced by Cys. In contrast,
in case 5, at position 209, the hydrophilic uncharged amino acid
Thr took the place of the positive charged Arg. Finally, mutants
R158G (case 3) and E258G (case 4) showed no DNA binding
activity. The substituted amino acids in these specimens also
belonged to different classes. More specifically, the positively
charged Arg and the negatively charged Glu were replaced by the
uncharged hydrophilic Gly.
Group B
Thep53 mutants ofthis group, A138D, A138S and V173E, did not
interact with the MDM2-p53RE. It is notable that the first two
cases possessed a point mutation at the same codon that changed
the hydrophobic amino acidAla to the negatively chargedAsp and
hydrophilic uncharged Serrespectively. The third member (case 8)
had a similar substitution as in case 6; the hydrophobic amino acid
Val was replaced by the negatively charged Glu.
Group C
As we expected, mutant p53 in case 9, which had a frameshift
mutation at codon 195, did not bind the p53RE, whereas sample
12, which produced the wt p53, interacted strongly with the
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element. Nuclear extracts from the remaining specimens 10 and
11, which contained mutants R273H and C275Y, showed strong
binding with the p53RE. Both mutations produced amino acid
substitutions with similar (-R) residual groups. However, it should
be mentioned that the last two samples maintained the wt p53
allele and therefore we cannot exclude the possibility, as we will
discuss later, of DNA binding being achieved by p53 oligomers
containing wt and mtp53 proteins (Stenger et al, 1992).
Relationship between DNA binding abilities of p53
mutants and MDM2 mRNA and protein levels (Table 1)
All the mutants that did not alter the net charge of the p53 mole-
cule (V157F, Y234C, R273H and C275Y) showed DNA-binding
activity, increased levels of MDM2 mRNA and MDM2 protein
overexpression. Only mutant R209T, which did not follow the
above rule, demonstrated similar findings. In contrast, three ofthe
four mutants (A138D, A138S and V173E), that altered the net
charge of the molecule, did not interact with the p53RE and were
not accompanied by MDM2 mRNA and MDM2 protein expres-
sion. In the remaining specimens, 3 and 4, MDM2 mRNA and
MDM2 proteins were overexpressed in spite of the fact that the
mutants R158G and E258G showed nobinding activity.
Transient transfection assays (Table 2, Figure 2)
To determine whetherspecific binding activity was correlated with
transactivation of the MDM2-pS3RE, we constructed four repre-
sentativep53 mutants: two from group A, V157F and R209T, and
one each from groupB, V173E, andC, R273H, and co-transfected
them with the luciferase reporter plasmid pGL2hmdm-HX-luc,
which contains the MDM2-pS3RE, into the p53-null human non-
small-cell lung carcinoma cell line H1299. Successful transfection
was verified with Western blot analysis of the mt p53 proteins. In
addition, in each experiment along with the p53 mutant plasmid
the wt p53 vector pCB6pS3wt and the pCB6 vector, as positive
and negative control, respectively, were co-transfected with the
reporter plasmid. The activity of the luciferase gene with each
mutant was tested with the wt p53 vector set at 100%. The
experiments were carried out independently three times with
the same results:
Group A
Mutant p53 V157F enhanced the luciferase activity of
pGL2hmdm-HX-luc at about 72% of the wt p53 vector, whereas
mutant R209T, which was detected in a small-cell carcinoma and
showed a strong interaction with the responsive element, failed to
stimulate it in the H1299 cell culture (Table 2, Fig. 2). These data
and those of others (see Discussion) suggest that the biological
and biochemical functions of p53 mutants are dependent on the
specific missense mutations acquired in thep53 gene and probably
the cellular environment in which they act.
Group B
As we expected mtp53 V173E, which failed to bind the p53RE in
the bandshift assay, was also unable to transactivate it.
Group C
As we mentioned, p53 mutant R273H, in case 10, was accompa-
nied by the wt p53 allele. Thus, we could not exclude the
possibility that DNA binding was achieved by heterotetramers
containing the normal and mt p53 proteins (Stenger at al, 1992).
Therefore, to clarify the picture we performed two kinds ofexper-
iments: first, we co-transfected the mt p53 plasmid alone with the
reporter plasmid and then the mt with the wt p53 at ratios 1:1 and
4:1. The total amount of transfected mutant and wt p53 plasmid
DNA was always 1 jg. As shown in Table 2 and Figure 2 mutant
R273H was unable alone to activate the MDM2-p53RE. However,
when mt and wtp53 plasmids were mixed at ratios 1:1 and 4:1 and
co-transfected with the reporter plasmid the luciferase activity was
increased from basal levels to 40% and 61% respectively. This
result, as we will discuss later, suggests a dominant positive effect
ofinactive p53 mutant R273H over wt p53.
DISCUSSION
In the present work, we examined the ability of mutant p53
proteins derived from selected lung carcinomas to bind the
MDM2-pS3RE. The findings were correlated with MDM2 mRNA
and protein levels. Furthermore, we constructed four of these p53
mutants and studied their transactivation abilities by co-trans-
fecting them with a reporter plasmid carrying the MDM2-pS3RE
into thep53 null non-small-cell lung carcinoma cell line (NSCLC)
H1299.
Selection was based on certain criteria that allowed us the study
of a homogeneous cancerous population as far as p53 and MDM2
expression is concerned. The cases were placed in three groups
(see Materials and methods).
DNA-binding experiments revealed that three out of the five
p53 mutants of group A (cases 1, 2 and 5) retained their DNA-
binding properties. Their mutations were detected at codons 157
(V->F), 234 (Y->C) and 209 (R -*T). As all these cases showed
overexpression of various MDM2 gene products due to increased
transcription and not to MDM2 gene amplification, we suggested
that certain p53 missense mutations, apart from stabilizing p53
(Zambetti and Levine, 1993; Gottlieb and Oren, 1996), generate
proteins that may maintain several of the wt p53 properties and
possibly acquire novel ones. The molecular basis ofthe effect that
missense mutations have on the behaviour ofp53 is not clear. One
possible explanation relies on the charge difference they introduce
into the p53 amino acid sequence. Interestingly, the substitutions
in p53 mutants V157F and Y234C were conservative and thus did
not alter the net charge of molecule. Similar were the findings of
Zhang et al. (1993a), Park et al. (1994) and Niewolik et al. (1995).
In their studies 'hotspot' p53 mutants, derived from different cell
lines, were tested for their ability to bind the original consensus
p53 DNA binding site (p53 CON) (Funk et al, 1992). The mutants
with DNA-binding activity had substitutions that retained the net
charge of p53 and, furthermore, they maintained the ability to
transactivate the p53 CON. In contrast, although the amino acid
change in p53 mutant R209T was non conservative, it interacted
with the MDM2-p53RE strongly. A probable interpretation could
reside on the secondary structure that this substituation partic-
ipates and the context in which this structure folds. Thus, position
209 lies in a 3-turn of the ,B-sandwich region ofp53 and the rela-
tive frequency of occurrence for Thr in ,B-turn is higher than Arg
(Creighton, 1984). It is therefore possible that this particular
substitution does not disrupt the secondary structure of the [-turn
and the conformation ofp53 protein generally. Crook et al. (1994)
studying the growth and transformation suppression functions ofa
large series of mutants observed that two tumour-derived point
mutants, p53 R175P and R181L, activated the MDM2-p53 RE as
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wt p53 did in primary rat embryo fibroblasts and Saos-2 cells.
They detected, by Western blotting, elevated levels of several
MDM2 protein isoforms. Both mutations were non-conservative
and concerned the highly sensitive in alterations loop L2 and a-
helix HI of the DNA binding domain of p53 (Cho et al, 1994).
Interestingly, both substitutions have a higher relative frequency of
occurrence in the aforementioned secondary structures than Arg
(Creighton, 1984). Three additional reports by Chen et al (1993),
Ory et al (1994) and Kawamura et al (1996) provide evidence that
could support both sides. These groups studied the biological
properties of several p53 mutants and observed a diversity in their
functions making the picture of mutants p53 behaviour much more
complex. Our opinion is that net charge difference is an important
factor in predicting the binding behaviour of mt p53 as all the
mutants in the present work that did not associate with the respon-
sive element (mutants R158G and E258G from group A and all the
mutants of group B) had substitutions that altered its net charge.
However, steric effects, hydrophobicity and interaction with other
proteins may also play a role.
The binding affinity of the mutants we examined was similar to
that of the in vitro translated wt p53 used as control (Figure lB,
lane 3). Niewolik et al. (1995) examining the affinity ofp53 mutant
proteins for the MDM2-p53RE, noticed a more than ten-fold
reduction in their binding activity. These differences may reflect
either a conformational and/or cell type specific effect. Several
investigators have shown that wt and mt p53 may regulate certain
promoters in a specific cell type manner (Grinsberg et al, 1991;
Santhanam etal, 1991; Chin et al, 1992; Subler et al, 1992; Mack et
al, 1993; Haupt et al, 1996; Rowan et al, 1996); for example the
PCNA promoter was not repressed by wt p53 in the study of Mack
et al (1993) using cervical epithelium cells but the same promoter
was repressed by wt p53 in the study of Subler et al (1992) using
Hela or Vera cells. Rowan et al. (1996) demonstrated that mutant
p53 R175P could induce growth arrest but not apoptosis in Saos-2
and H1299 cells, whereas HeLa and H358 cells retained some
apoptotic function after R175P expression. This cell-type effect
may be due to specific cellular co-factors that couple with the
activated form ofp53, thus modulating its function.
The p53 mutant proteins in specimens 3 and 4, which also
showed MDM2 overexpression, did not bind theMDM2-pS3RE. It
seems that in these cases MDM2 overexpression is due either to a
p53-independent mechanism or to an indirect mode of action of
mt p53. The basis for both mechanisms possibly relies on the
way MDM2 gene is organized. The MDM2 gene possesses two
promoters P1 and P2 (Figure 3). P1 is ap53-independent promoter
located upstream from exon 1 and is active at basal constitutive
levels and P2 is the p53-dependent promoter located in intron 1
and contains the p53 RE accompanied by the general transcription
element TATA box (Zauberman et al, 1995a). In the first case, the
p53-independent mechanism ofMDM2 overexpression is possibly
activated by alterations in the regulatory elements ofP1. Although
our experiments did not reveal MDM2 gene amplification, we
cannot exclude the possibility of regional gene alterations (e.g.
deletion ofsilencer elements), which could participate in this puta-
tive mechanism. In the second, mutant p53 may favour transcrip-
tion in a general way. This assumption is based on several
observations. It has already been shown that the N-terminus of wt
p53 directly interacts with TBP (TATA-binding protein) and other
general transcription factors (Martin et al, 1993; reviewed by:
Zambetti and Levine, 1993; Gottlieb and Oren, 1996; Ko and
Prives, 1996; Oren and Prives, 1996; Levine, 1997). The presence
of p53 binding sites near the TATA element possibly allows the
nucleation on these promoters, thus enhancing transcriptional
activity. In the case of mtp53 defective in DNA binding, the inter-
action with these transcription factors may be preserved and a
general activation of P2 may be achieved. In accordance with this
speculation is the finding ofMartinet al (1993), who observed that
mt p53 V218G, which was bound with TBP, did activate a
promoter with p53 binding sites in vivo, although the DNA
binding activity of the mutant was abolished.
The findings in group A were further enforced by the observa-
tions in group B. The mutants in this group (A138D, A138S and
V173E) did not bind the MDM2-pS3RE and were not accompa-
nied by MDM2 expression. Codon 138 is localized near the
transcriptional activation domain ofp53. The integrity ofthe trans-
activation domain is shown to be critical for 'gain offunction' p53
mutants (Lin et al, 1995). Possibly these mutants, apart from
losing their DNA binding properties, suffer a conformational
change in the N-terminus domain that interferes with their ability
to interact with factors of the transcription machinery. Codon 173
is involved in stabilizing interactions between loops L2 and L3 of
p53 protein. Mutations at this region are considered among the
most disruptive for p53 functions (Prives, 1994).
The four samples included in the heterogeneous group C
provided additional evidence concerning the functions of mt and
wt p53. In sample 9, p53 did not show binding activity because
the frameshift mutation at codon 195 altered its reading frame
producing either a non-functional mRNA or an altered protein
with unknown functions. MDM2 overexpression in sample 12 is
possibly caused by constant stimulation ofthe MDM2 gene by the
accumulated wt p53. Normally wt p53 has a short half-life
(Zambetti and Levine, 1993; Gottlieb and Oren, 1996), butcellular
stress (Hall et al, 1996) and certain proteins, including MDM2, can
induce stabilization ofthe protein (Momand et al, 1992). Recently,
Haupt et al (1996) demonstrated that MDM2 overexpression in
H1299 cells resulted in effective protection from apoptosis. Loss
of p53 induced apoptosis even without a concomitant loss ofGI
arrest could contribute to cancer progression. This mechanism of
action could exist in our case as well. Finally, p53 mutants R273H
and C275Y behaved in a similarmanneras mutants in samples 1, 2
and 5. As these cases retained the wt p53 allele we hypothesized
that MDM2 protein isoform overexpression was achieved either
by the mutant in a wt p53-independent manner (wt p53 allele non-
functional) or by a dominant positive effect of the mt p53 on the
functional wt p53.
To examine the credibility ofthe hypotheses we have suggested
above, we constructed four of these p53 mutants, two from group
A, V157F and R209T, and one from group B, V173E, and C,
R273H, co-transfected them with a luciferase reporter plasmid
carrying the MDM2-pS3RE, in the p53 null H1299 cell line and
studied their transactivation abilities. Mutant V157F enhanced
luciferase expression at about 72% (Figure 2, Table 2) of the wt
p53 vector conforming our initial speculation that, MDM2 over-
expression in certain lung carcinomas may be due to a 'gain of
function' mutant p53 phenotype (Gorgoulis et al, 1996a,b). In
contrast, mutant R209T, which showed a strong interaction with
the responsive element, failed to stimulate it. This finding may be
due to determinants of the H1299 cellular context that altered the
function of the protein. The effect of the cellular environment on
wt and mt p53 activities, as we mentioned, is gradually becoming
clearer (Oren and Prives, 1996). In the present case, R209T was
detected in a small-cell lung carcinoma (SCLC), whereas H1299 is
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a non-small-cell lung carcinoma (NSCLC)-derived cell line.
Although from a histogenetic point of view all histological vari-
ants of bronchogenic carcinoma have a common origin, SCLCs
are much more aggressive and are treated differently than
NSCLCs (Mackay et al, 1991). Whereas transfection with V173E,
as we expected, showed no surprises (Figure 2, Table 2) transfec-
tion with R273H showed some interesting results. More specifi-
cally, when R273H was introduced in the cells alone with the
reporter plasmid no luciferase activity was observed but when
R273H and wt p53 expression vectors were mixed in a 1:1 and 4:1
ratio, luciferase activity was increased gradually from basal levels
to 40% and 61% respectively (Figure 2, Table 2). This finding
conformed the hypothesis we stated and suggested that dominant
negative inhibition by mt p53 is not the rule and that certain p53
mutants, depending on the binding element and possibly the
appropriate environment, have a 'positive effect' on wt p53 func-
tion. Similar were the results of Zhang et al (1993b) using the
p53CON element. In their study, they proposed that the relative
ratio of mt to wt p53 in the heterotetramers they form is important
for transactivation.
Taking together the above data, we propose the following
hypothesis (Figure 3): in a normal cell under stress, MDM2 can be
transactivated only when wt p53 has activated the targets that
mediate its action (e.g. gadd45, waf-Jlcip-1). When the cell
contains relatively large amounts ofwt p53, it binds transiently the
p53RE of MDM2, triggering MDM2 expression that eventually
terminates p53 cycle arrest mediated signal. In contrast, constantly
elevated levels of mt or wt p53 in lung carcinoma cells perma-
nently stimulate the MDM2 gene (directly or indirectly),
producing high levels ofMDM2 mRNA. Excess MDM2 mRNA is
probably responsible, via complex mechanisms (Barak et al, 1994;
Zauberman et al, 1995a), for the production of various MDM2
proteins, several of which do not participate in the autoregulatory
loop with p53 (Gorgoulis et al, 1996b). These proteins possibly
add novel oncogenic properties to the cell (Sigalas et al, 1996).
In conclusion, the present study suggests that deregulation of
the p53/MDM2 autoregulatory feedback loop, in a subset of lung
carcinomas, may be due to either a 'gain of function' mt p53
phenotype or to a dominant positive effect of certain p53 mutants
on the wt p53 protein.
ACKNOWLEDGEMENTS
The authors wish to thank Professor M Oren for his kind sugges-
tions in the course of the study and for providing the expression
vector pCB6p53wt, the reporter plasmid pGL2hmdm2-HX-luc
and the H1299 cell line. We also wish to thank Dr PP Sfikakis and
Dr P Panagiotidis for technical support, Dr F Mavrommatis and N
Rezaie for their helpful critisism in the manuscript and, also
Dr DP Lane for providing antibody DOI.
REFERENCES
Barak Y, Gottlieb E, Juven-Gershon T and Oren M (1994) Regulation ofmdm2
expression by p53: altemative promoters produce transcripts with non identical
translation potential. Genes Dev 8: 1739-1749
Bayle JH, Elenbaas B and Levine AJ (1995) The carboxyl-terminal domain ofp53
protein regulates sequence-specific DNA binding through its non-specific
nucleic acid-binding activity. Proc NatlAcad Sci USA 92: 5729-5733
Buckbinder L, Talbott R, Valesco-Miguel S. Takenaka I, Faha B, Seizinger BR and
Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53.
Nature 377: 646-649
Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA and Albitar M (1993)
The human MDM2 oncogene is overexpressed in leukemias. Blood 82:
2617-2623
Bueso-Ramos CE, Manshouri T, Haidar M, Huh YO, Keating MJ and Albitar M
(1995a) Multiple pattems ofMDM2 deregulation in human leukemias:
Implications in leukemogenesis and prognosis. Leuk Lymph 17: 13-18
Bueso-Ramos CE, Yang Y, Manshouri T, Feltz L, Ayala A, Glassman AB and
Albitar M (1995b) Molecular abnormalities ofMDM-2 in human sarcomas.
Int J Oncol 7: 1043-1048
Bueso-Ramos CE, Manshouri T, Yang Y, McCown P, Ordonez NG, Sneige N and
Albitar M (1996) Abnormal expression ofmultiple MDM-2 proteins in breast
carcinomas. Breast Cancer Res Treat 85: 29-40
Chen JY, Funk DK, Wright WE, Shay JW and Minna JD (1993) Heterogeneity of
transcriptional activity ofmutant p53 proteins and p53 DNA target sequences.
Oncogene 8: 2159-2166
Chen X, Bargonetti J and Prives C (1995) p53 through p21 (WAFI/CIPi), induces
cyclin Dl synthesis. Cancer Res 55: 4257-4263
Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation ofactivity of
the promoter ofthe human MDRl gene by Ras and p53. Science 255:
459-462
Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal Structure of a p53
Tumour Suppressor-DNA Complex: Understanding Tumorigenic Mutations.
Science 265: 346
Creighton TE (1984) Proteins Structures andMolecular Properties p. 235 WH
Freeman:
Crook T, Marston NJ, Sara EA and Vousden KH (1994) Transcriptional activation by
p53 correlates with suppression ofgrowth but not transformation. Cell 79:
817-827
Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of
angiogenesis in fibroblast by p53 regulation ofthrombospontin- 1. Science 265:
1582-1584
Deb SP, Munoz RM, Brown DR, Subler MA and Deb S (1994) Wild-type human
p53 activates the human epidermal growth factor receptor promoter. Oncogene
9:1341-1349
Deng EC and NickoloffJA (1992) Site-directed mutagenesis of virtually any
plasmid by eliminating a unique restriction site. Anal Biochem 20: 81
Deffie A, Wu H, Reinke V and Lozano G (1993) The tumor suppressor p53 regulates
its own transcription. Mol Cell Biol 13: 3415-3423
Dittmer D, Parti S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine
AJ (1993) Gain offunction mutations in p53. Nature Genet 4(1): 42-46
El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent GM, Lin D,
Merker WE, Kinz KW and Volgenstein B (1993) WAFl, a potential mediator
ofp53 tumor suppression. Cell 75: 817-825
Fontana X, Ferrari Abbes M, Monticelli Namer M and Bussiere F (I1994) Etude de
l'amplification du gene mdm-2 dans les tumeurs primitives du cancer du sein.
Bull Cancer 81: 587
Foulkes WD, Stamp GWH, Afzal S, Lalani N, McFarlane CP, Trowsdale J and
Campbell IG (1995) MDM2 overexpression is rare in ovarian carcinoma
irrespective ofTP53 mutation status. BrJ Cancer 67: 551-559
Funk WD, Pak DT, Karas RH, Wright WE and Shay JW (I1992) A transcriptonally
active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:
2866-2871
Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA
and Kittas C (1995a) Molecular analysis ofp53 gene in laryngeal pre-
malignant and malignant lesions: p53 protein immunohistochemical expression
is positively related to proliferating cell nuclear antigen labelling index.
Virchows Archiv 426: 339-344
Gorgoulis V, Sfikakis PP, Karameris A, Papastamatiou H, Trigidou R, Veslemes M,
Spandidos DA, Sfikakis P and Jordanoglou J (1995b) Molecular and
immunohistochemical study ofclass I growth factor receptors in squamous cell
lung carcinomas. Path Res Pract 191: 973-981
Gorgoulis V, Rassidakis G, Karameris A, Papastamatiou H, Trigidou R, Veslemes M,
Rassidakis A and Kittas C (1996a) Immunohistochemical and molecular
evaluation ofthe MDM2 gene product in bronchogenic carcinoma. Mod Path 9:
544-554
Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Rassidakis A, Spandidos
DA and Kittas C (1996b) A molecular and immunohistochemical study ofthe
MDM2 protein isoforms andp53 gene product in bronchogenic carcinoma.
JPath 180: 129-137
Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim
BiophysActa 1287: 77-102
Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in thep53
tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis.
Cancer Res 54: 4855-4878
C CancerResearch Campaign 1998 British JournalofCancer(1998) 77(3), 374-384384 VG Gorgoulis etal
Grinsberg D, Mechta F, Yaniv M and Oren M (1991) Wild-type p53 can down-
modulate the activity ofvarious promoters. Proc NatlAcadSci USA 88:
9979-9983
Halazonetis TD and Kandil AN (1993) Conformational shifts propagate from the
oligomerization domain ofp53 to its tetrameric DNA binding domain and
restore DNA binding to select p53 mutants. EMBO J 12: 5057-5064
Hall P, Meek D and Lane DP (1996) p53-integrating the complexity. JPath 180:
1-5
Haupt T, Barak Y and Oren M (1996) Cell type specific inhibition ofp53-mediated
apoptosis by mdm2. EMBO J 15: 1596-1606
Hinds P, Finlay C and Levine AJ (1989) Mutation is required to activate the p53
gene for cooperation with the ras oncogene and transformation. J Virol 63:
739-746
Hsiao M, Low J, Dom E, Ku D, Pattengale P, Yeargin J and Haas M (1994) Gain of
function mutations ofthe p53 gene induce lympohematopoietic metastasic
potential and tissue invasiveness. Am JPathol 145: 702-714
Kastan MB, Zhan Q, El-Diery WS, Canrier F, Jacks T, Walsh WV, Plunkett BS,
Volgenstein B and Fomance AJ Jr (1992) A mammalian cell cycle checkpoint
pathway utilizing p53 and GADD45 is defective in ataxia-telegiectasia. Cell
71: 587-597
Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M and Fujinaga K
(1996) The 273rd codon mutants ofp53 show growth modulation activities
not correlated with p53-specific transactivation activity. Oncogene 12:
2361-2367
Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054-1072
Levine AJ (1997) p53, the cellular gatekeeper for growth and devision. Cell 88:
323-331
Lin J, Teresky AK and Levine AJ (1995) Two critical hydrophobic amino acids in
the N-terminal domain ofthe p53 protein are required for the gain offunction
phenotypes ofhuman p53 mutants. Oncogene 10: 2387-2390
Mack DH, Vartikar J, Pipas JM and Laimins LA (1993) Specific repression of
TATA-mediated but not initiator-mediated transcription by wild-type p53.
Nature 363: 281-283
Mackay B, Lukeman JM and Ordofiez N (1991) Tumors ofthe Lung WB Saunders:
Philadelphia, USA
Martin DW, Munoz RM, Subler MA and Deb S (1993) p53 binds to the TATA-
binding protein-TATA complex. JBiol Chem 268: 13062-13067
Martin K, Trouche D, Hagemeier C, Sorensen TS, LaThangue NB and Kouzarides
T (1995) Stimulation ofE2F1/DP1 transcriptional activity by MDM2
oncoprotein. Nature 375: 691-694
Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L and Benchimol S (1984)
Isolation and characterization ofa human p53 cDNA clone: expression ofthe
human p53 gene. EMBO J3: 3257-3262
Michalovitz D, Halevy 0 and Oren M (1991) p53 mutations: gain or losses? JCell
Biochem 45: 22-29
Milner J, Medcalf EA and Cook AC (1991). Tumor suppressorp53: analysis ofwild
type and mutant p53 complexes. Mol Cell Biol 11: 12-19
Miyashita T and Reed JC (1995) Tumor suppressorp53 is a direct transcriptional
activator ofthe human bax gene. Cell 80: 293-299
Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The MDM2
oncogene product forms a complex with the p53 protein and inhibits p53-
mediated transactivation. Cell 69: 1237-1245
Morris GF, BischoffJR and Mathews MB (1996) Transcriptional activation ofthe
human proliferating-cell nuclear antigen promoter by p53. Proc NatlAcadSci
93: 895-899
Muller BF, Paulsen D and Deppert W (1996) Specific binding ofMARISAR DNA-
elements by mutantp53. Oncogene 12: 1941-1952
Niewolik D, Vojtesek B and Kovarik J (1995) p53 derived from human tumour cell
lines and containing distinct point mutations can be activated to bind its
consensus target sequences. Oncogene 10: 881-890
Oca Luna RM, Wagner DS and Lozano G (1995) Rescue ofearly embryonic
lethality in mdm2-deficient mice by deletion ofp53. Nature 378: 203-205
Olson D, Marechal V, Momand J, Chen J, Romochi C and Levine AJ (1993)
Identification and characterization ofmultiple mdm2 proteins and mdm2 p53
protein complexes. Oncogene 8: 2353-2360
Oren M and Prives C (1996) p53: upstream, downstream and offstream. Review of
the 8th p53 workshop (Dundee, 5-9 July 1996). Biochim Biophys Acta 1288:
R13-R19
Ory K, Legros Y, Auguin C and Soussi T (1994) Analysis ofthe most representative
tumour-derived p53 mutants reveals that changes in protein conformation are
not correlated with loss oftransactivation or inhibition ofcell proliferation.
EMBO J 13: 3496-3504
Osifchin NE, Jiang D, Ohtani-Fujita N, Fujita T, Carroza M, Kim S-J, Sakai T and
Robbins PD (1994) Identification ofap53 binding site in the human
retinoblastoma susceptibility gene promoter. JBiol Chem 269: 6383-6389
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth
JA, Deisseroth AB, Zhang W-W, Kruzel E and Radinsky R (1995) Wild type
human p53 and a temperature sensitive mutant induce fas/APOl expression.
Mol Cell Biol 15: 3032-3040
Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL and Koeffler
HP (1994) Transactivational and DNA binding abilities ofendogenous p53 in
p53 mutant cell lines. Oncogene 9: 1899-1906
Price BD and Park SJ (1994) DNA Damage Increases the Levels ofMDM2
Messenger RNA in wtp53 Human Cells. CancerRes 54: 896-899
Prices C (1994) How loops, f sheets, and a helices help us to understand p53. Cell
78: 543-546
Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M and Vousden H (1996)
Specific loss ofapoptotic but not cell cycle arrest function in a human tumor
derived p53 mutant. EMBO J 15: 827-838
Sambrook J, Fritsh EF and Maniatis T (1989) Molecular Cloning. A Laboratory
Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press
Santhanam U, Ray A and Sehgal PB (1991) Repression ofthe interleukin 6 gene
promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl
AcadSci USA 88: 7605-7609
Shin TH, Paterson AJ and Kudlow JE (1995) p53 stimulates transcription from the
human transforming growth factor-a promoter: a potential growth-stimulatory
role forp53. Mol Cell Biol 15: 4694-4701
Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J (1996) Alternatively
spliced mdm2 transcripts with loss ofp53 binding domain sequences:
Transforming ability and frequent detection in human cancer. Nature Med 2:
912-917
Spandidos DA, Zoumpourlis V, Zachos G, Toas SH and Halazonetis TD (1995)
Specific recognition ofa transcriptional element within the human H-ras proto-
oncogene by the p53 tumour suppressor. IntJ Oncol 7: 1029-1034
Stenger JE, MayrJA, Mann K and Tegtmeyer P (1992) Formation ofstable
homotetramers and multiples oftetramers. Mol Carcinogen 5: 102-106
Subler MA, Martin DW and Deb S (1992) Inhibition ofviral and cellular promoters
by human wild-type p53. J Virol 66: 6164-6170
Vogelstein B and Kinzler KW (1992) p53 Function and Dysfunction. Cell 70:
523-526
World Health Organization (1982) The World Health Organization histologic typing
oflung tumours. Am J Clin Path 77: 123-136
Wu X, Bayle JH, Olson D and Levine AJ (1993) The p53-mdm2 autoregulatory
feedback loop. Genes Dev 7: 1126-1132
Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM
(1995) Interaction between the retinoblastoma protein and the oncoprotein
MDM2. Nature 375: 694-698
Zakutt-Houri R, Bienz-Tadmor B, Givol D and Oren M (1985) Human p53 cellular
tumour antigen: cDNA sequence and expression in COS cells. EMBOJ4:
1251-1255
Zambetti GP and Levine AJ (1993) A comparison ofthe biological activities of
wild-type and mutant p53. FASEB J7: 855-865
Zauberman A, Flusberg D, Haupt Y, Barak Y and Oren M (1995a) A functional p53-
responsive intronic promoter is contained within the human mdm2 gene.
NucleicAcids Res 23: 2584-2592
Zauberman A, Lubp A and Oren M (1995b) Identification ofp53 target genes
through immune selection ofgenomic DNA: The cyclin G gene contains two
distinct p53 binding sites. Oncogene 10: 2361-2366
Zhang W, Funk WD, Wright WE, Shay JW and Deisseroth AB (1993a) Novel DNA
binding ofp53 mutants and their role in transcriptional activation. Oncogene 8:
2555-2559
Zhang W, Shay JW and Deisseroth A (1993b) Inactive p53 mutants may enhance the
transcriptional activity of wtp53. Cancer Res 53: 4772-4775
Zhang W, Randhawa GS, Gau J-P, Shay JW and Deisseroth AB (1995) The first
intron ofhuman H-ras is regulated by p53: Mediation of specific activation by
a p53-binding element. IntJ Oncol 7: 1021-1028
British Journal ofCancer (1998) 77(3), 374-384 C Cancer Research Campaign 1998